EP Patent

EP2440560A1 — The succinate of tenofovir disoproxil

Assigned to Ultimorphix Technologies BV · Expires 2012-04-18 · 14y expired

What this patent protects

The present invention provides a succinate of Tenofovir disoproxil, methods for the preparation thereof and its use in pharmaceutical applications, in particular in anti-HIV medicaments. The succinate of Tenofovir disoproxil can be used in combination with other anti-HIV medicame…

USPTO Abstract

The present invention provides a succinate of Tenofovir disoproxil, methods for the preparation thereof and its use in pharmaceutical applications, in particular in anti-HIV medicaments. The succinate of Tenofovir disoproxil can be used in combination with other anti-HIV medicaments such as Efavirenz and Emtricitabine. The invention also provides methods for the treatment of HIV using the succinate of Tenofovir disoproxil medicaments such as Efavirenz and Emtricitabine.

Drugs covered by this patent

Patent Metadata

Patent number
EP2440560A1
Jurisdiction
EP
Classification
—
Expires
2012-04-18
Drug substance claim
No
Drug product claim
No
Assignee
Ultimorphix Technologies BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.